NCT02744976View on ClinicalTrials.gov

Coronary Artery Disease Progression in Patients With Prediabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

September 30, 2021

Conditions
Coronary Artery DiseaseAtherosclerosisPrediabetic State
Interventions
DRUG

Metformin

In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months

BEHAVIORAL

Lifestyle recommendations

Standard lifestyle recommendations

Trial Locations (1)

Unknown

Pauls Stradins Clinical University hospital, Riga

All Listed Sponsors
lead

Pauls Stradins Clinical University Hospital

OTHER

NCT02744976 - Coronary Artery Disease Progression in Patients With Prediabetes | Biotech Hunter | Biotech Hunter